January 31, 2019 8:29am
On the last day of January
That’s tied to share pricing
Pre-open indications: 2 BUY, 2 SELLs and 3 trades
News: REGENXBIO (RGNX) the U.S. (FDA granted Rare Pediatric Disease Designation to RGX-181. RGX-181 is a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene.
I answer one question, in which company should investors put, keep and commit their money!
I focus on indication analysis; an indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation. The sole provision is that it provides insight to provide some vision into a likely course of action.
U.S. stock index futures point to a mixed open
Dow futures are DOWN -0.16% (- 40 points) and NASDAQ futures are UP +0.52% (+36 points)
U.S. stock index futures pointed to a mixed start to trading on Thursday after the Fed kept interest rates unchanged.
European stocks lost some of the earlier steam as Brexit continues to take center stage. EU officials have told the U.K. that the current Withdrawal Agreement will not be reopened, as some U.K. lawmakers have demanded.
Asian stock markets closed mixed on Thursday.
Data docket: weekly jobless claims and an employment cost index are due at 8:30 a.m. ET, Chicago PMI data are due at 9:45 a.m., and new home sales data are expected at 10 a.m.
The iShares Nasdaq Biotechnology (IBB) is NOT indicating
The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +0.3% UPSIDE
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating
The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.2% UPSIDE
Let’s leave this month behind, although it wasn’t a bad month’s worth of sessions … get on to February and Q4 quarterly LPS (loss-per-share) earnings and the peaks and valleys behind - hopefully!
It will be all about expectation - the idea that a bullish start to the year means a dazzling performance in the next 11 months as, quarterly estimates are be missed or met.
- In 21 sessions in January – there was 12 positive closes, 1 neutral, 1 holiday and 7 negative closes – so far!
Wednesday’s evening post, “investors need to comprehend the refracting light in the prism of share pricing. Sentiment is where trading categorizes the delusion of pricing actions. Thank the Fed Reserve for the late session surge …Don’t get me wrong, I welcome the “rectified” upside however; it’s still the battle of the oversold becoming the overbought and their forthcoming regression>”
Last night’s percentage (%) indicators:
- Ranged of the 35 upside was +0.06% (KOOL +$0.0002) to +13.73% (CUR +$0.05) while the 5 downside ranged from -0.19% (AST) to -5.40% (VYGR) with 5 flat close (ADVM, OSIR, PSTI, STML and RENE.L).
- 8 out of the 35 upside had higher (than the 3 month average) volume
- 4 out of the 5 downside experienced greater volume (than the 3 month average)
Companies in my headlights – It’s your decision; I provide an idea and context:
Asterias Biotherapeutics (NYSEMKT: AST) closed down -$0.0019 up +$0.28 or +39.25% to $ on news of BioTime’s (NYSEMKT: BTX) OncoCyte (OCX: NYSE American) positive results on its lung cancer liquid biopsy test. There is a negative -$0.03 or-2.87% aftermarket indication. Tuesday’s incline was steep and traders will reap from the share pricing – Maintaining SELL;
BioTime (NYSEMKT: BTX) closed up +$0.03 to $1.42 after Tuesday’s +$0.49 or +55.46% to $1.39. BioTime’s (NYSEMKT: BTX) OncoCyte (OCX: NYSE American) announced positive results on its lung cancer liquid biopsy test. The incline is steep and traders will reap from the share pricing – Maintaining SELL;
Voyager Therapeutics (VYGR) closed down -$0.60 to $10.52 after Tuesday’s +$3.08 or +38.31% to $11.12 on news of a strategic collaboration was announced focusing on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia after Monday’s down -$0.41 to $8.04. There is a positive +$0.26 or +2.47% aftermarket indication –SELL to BUY;
CRISPRS Therapeutics (CRSP) closed up +$1.27 to $32.24 after Tuesday’s -$0.20 to $30.97, Monday’s -$2.03 to $31.17 following Friday’s +$0.91 to $33.20 after Thursday’s +$0.89 to $32.29 and last Wednesday’s -$1.68 to $31.40 – TRADE;
Editas Medicine (EDIT) closed up +$0.99 to $21.28 after Tuesday’s -$0.37 to $30.97, Monday’s -$0.80 to $20.66, Friday’s +$0.13 to $21.46, Thursday’s +$1.23 to $21.33 and last Wednesday’s -$0.85 to $20.10. – TRADE;
Intellia Therapeutics (NTLA) closed down -$0.47 to $12.99 -$1.30 to $13.46 following Friday’s +$0.38 to $14.76 after Thursday’s +$0.60 to $14.38, Wednesday’s -$0.38 to $13.68 and last Tuesday’s -$1.04 to $14.16. No indication yet, it is getting cheaper – TRADE;
REGENXBIO (RGNX) closed up +$1.13 to $42.94 and this a.m. announced the U.S. FDA granted Rare Pediatric Disease Designation to RGX-181. RGX-181 is a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene. In addition to the Rare Pediatric Disease Designation, REGENXBIO previously received Orphan Drug Designation from the FDA for RGX-181 - BUY;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.